ZFIN ID: ZDB-FISH-150901-14790
Fish name: f2Tg
Genotype: f2Tg
Targeting Reagent: none
HUMAN DISEASE MODELED by f2Tg
No data available
GENE EXPRESSION
Gene expression in f2Tg
Protein expression
Antibody Antigen Genes Structure Conditions Figures
zn-5 standard conditions Fig. 1,  Fig. 2,  Fig. 3,  Fig. 4,  Fig. 5,  Fig. 6 from Andersen et al., 2015
Ab-S46 chemical treatment: 4-(diethylamino)benzaldehyde Fig. 5 with image from Rydeen et al., 2016
Fig. 1 with image from Waxman et al., 2008
Ab2-fn control Fig. 3 with image from Sallin et al., 2016
Ab-MF20 standard conditions Fig. 6 with image from Colombo et al., 2017
Fig. 4 with image from George et al., 2015
Ab1-N2.261 control Fig. 3 with image from Sallin et al., 2016
Ab1-mef2 surgical manipulation: pericardial cavity Fig. 1 with image from de Preux Charles et al., 2016
Ab1-mef2 control Fig. 1 with image from de Preux Charles et al., 2016
Ab1-igf1r control Fig. 6 with image from Sallin et al., 2016
Ab1-mcm5 control Fig. 1 with image,  Fig. 7 with image from de Preux Charles et al., 2016
Ab1-mcm5 surgical manipulation: pericardial cavity Fig. 1 with image,  Fig. 7 with image,  Fig. 8 with image from de Preux Charles et al., 2016
Ab-S46 standard conditions 12 figures with image from 10 publications
Ab1-mcm5 chemical treatment by injection: lipopolysaccharide Fig. 4 with image from de Preux Charles et al., 2016
Ab-S46 heat shock Fig 8 with image from Song et al., 2019
Fig. 4 with image from Rydeen et al., 2016
zn-5 chemical treatment: pharmaceutical Fig. 2,  Fig. 3,  Fig. 5,  Fig. 6 from Andersen et al., 2015
Ab2-kita kita standard conditions Fig. 2 from Verduci et al., 2014
PHENOTYPE
Phenotype in f2Tg
Phenotype Conditions Figures
atrium has extra parts of type cardiac muscle cell, abnormal chemical treatment: all-trans-retinoic acid Fig. 6 with image from D'Aniello et al., 2013
atrium cardiac muscle cell amount, normal chemical treatment: all-trans-retinol Fig. 8 with image from D'Aniello et al., 2015
atrium cardiac muscle cell decreased amount, abnormal chemical treatment by environment: doxorubicin Fig. 1 from Liu et al., 2014
atrium cardiac muscle cell decreased amount, abnormal chemical treatment: all-trans-retinoic acid Fig. 8 with image from D'Aniello et al., 2015
atrium cardiac muscle cell decreased amount, abnormal chemical treatment: all-trans-retinal Fig. 8 with image from D'Aniello et al., 2015
cardiac muscle cell apoptotic, abnormal chemical treatment by environment: doxorubicin Fig. 1 from Liu et al., 2014
cardiac muscle cell decreased amount, abnormal chemical treatment: all-trans-retinol Fig. 8 with image from D'Aniello et al., 2015
cardiac muscle cell decreased amount, abnormal chemical treatment: all-trans-retinal Fig. 8 with image from D'Aniello et al., 2015
cardiac muscle cell decreased amount, abnormal chemical treatment: all-trans-retinoic acid Fig. 8 with image from D'Aniello et al., 2015
cardiac muscle cell decreased volume, abnormal chemical treatment: pharmaceutical Fig. 6 from Andersen et al., 2015
cardiac muscle cell decreased volume, abnormal chemical treatment: pharmaceutical Fig. 3 from Andersen et al., 2015
cardiac muscle cell decreased volume, abnormal chemical treatment: pharmaceutical Fig. 6 from Andersen et al., 2015
cardiac muscle cell increased volume, abnormal chemical treatment: pharmaceutical Fig. 5 from Andersen et al., 2015
cardiac muscle cell increased volume, abnormal chemical treatment: pharmaceutical Fig. 5 from Andersen et al., 2015
cardiac muscle cell apoptotic process increased process quality, abnormal hypoxia Fig. 5 with image from Parente et al., 2013
cardiac muscle cell cell death increased process quality, abnormal hypoxia Fig. 6 with image from Parente et al., 2013
cardiac muscle cell cell population proliferation increased process quality, abnormal hypoxia Fig. 7 with image,  Fig. 8 with image from Parente et al., 2013
cardiac muscle cell re-entry into mitotic cell cycle increased occurrence, abnormal surgical manipulation: pericardial cavity Fig. 1 with image from de Preux Charles et al., 2016
cardiac ventricle has extra parts of type cardiac muscle cell, abnormal chemical treatment: all-trans-retinoic acid Fig. 6 with image from D'Aniello et al., 2013
cardiac ventricle has normal numbers of parts of type cardiac muscle cell, normal chemical treatment by environment: 3-(N-HYDROXYCARBOXAMIDO)-2-ISOBUTYLPROPANOYL-TRP-METHYLAMIDE Fig. 5 with image from Rydeen et al., 2016
cardiac ventricle morphology, abnormal chemical treatment: pharmaceutical Fig. 3 from Andersen et al., 2015
cardiac ventricle cardiac muscle cell decreased amount, abnormal chemical treatment: all-trans-retinoic acid Fig. 8 with image from D'Aniello et al., 2015
cardiac ventricle cardiac muscle cell decreased amount, abnormal chemical treatment: all-trans-retinol Fig. 8 with image from D'Aniello et al., 2015
cardiac ventricle cardiac muscle cell decreased amount, abnormal chemical treatment: all-trans-retinal Fig. 8 with image from D'Aniello et al., 2015
cardiac ventricle cardiac muscle cell decreased amount, abnormal chemical treatment by environment: doxorubicin Fig. 1 from Liu et al., 2014
compact layer of ventricle tissue remodeling increased occurrence, abnormal chemical treatment by injection: (1->3)-beta-D-glucan Fig. 4 with image from de Preux Charles et al., 2016
heart has extra parts of type cardiac muscle cell, abnormal chemical treatment: all-trans-retinoic acid Fig. 6 with image from D'Aniello et al., 2013
heart linear, abnormal chemical treatment: all-trans-retinol Fig. 8 with image from D'Aniello et al., 2015
heart cardiac muscle cell proliferation increased occurrence, abnormal surgical manipulation: pericardial cavity Fig. 1 with image from de Preux Charles et al., 2016
heart tissue remodeling increased occurrence, abnormal surgical manipulation: pericardial cavity Fig. 3 with image from de Preux Charles et al., 2016
heart contraction arrested, abnormal chemical treatment: pharmaceutical Fig. 6 from Andersen et al., 2015
heart contraction arrested, abnormal chemical treatment: pharmaceutical Fig. 5 from Andersen et al., 2015
heart contraction arrested, abnormal chemical treatment: pharmaceutical Fig. 2,  Fig. 5 from Andersen et al., 2015
heart contraction arrested, abnormal chemical treatment: pharmaceutical Fig. 3 from Andersen et al., 2015

CITATIONS  (78)

Your Input Welcome
We welcome your input and comments. Please use this form to recommend updates to the information in ZFIN. We appreciate as much detail as possible and references as appropriate. We will review your comments promptly.
Please check the highlighted fields and try again.
Thank you for submitting comments. Your input has been emailed to ZFIN curators who may contact you if additional information is required.
Oops. Something went wrong. Please try again later.